Background-Although
O xidative stress plays a central role in the pathogenesis of acute respiratory distress syndrome (ARDS), 1 a condition characterized by a time-dependent worsening of intrapulmonary inflammation and hypertension. [1] [2] [3] Principal among the reactive oxygen species (ROS) generated by oxidative stress is superoxide (O 2 ·Ϫ ), which reacts with nitric oxide (NO) to produce peroxynitrite (ONOO ·Ϫ ), thereby reducing bioavailable NO. 4 A reduction of NO availability promotes not only vasoconstriction but also the adhesion of leukocytes and platelets, which in turn release a battery of vasoconstrictors and cytokines, 1, 4 thereby exacerbating ongoing inflammatory cascades and the development of pulmonary hypertension. Adherent neutrophils and monocytes release tumor necrosis factor-␣ (TNF-␣) and interleukins (ILs), the blood levels of which are markedly elevated in patients with ARDS. 5 In turn, TNF-␣ and ILs and lipopolysaccharide (LPS) upregulate enzymes that generate O 2 ·Ϫ in cultured vascular tissues, in particular, NADPH oxidase. 6, 7 A selfperpetuating inflammatory cascade ensues.
ARDS is a difficult, if not intractable, condition to treat. 8 Because inflammation is the pathological hallmark of ARDS, 9 it would be reasonable to expect that nonsteroidal antiinflammatory drugs (NSAIDs) would be effective in treating ARDS. However, NSAIDs, in particular ibuprofen, have proved ineffective in reducing mortality associated with ARDS despite eliciting a profound inhibition of proinflammatory eicosanoids, such as thromboxane A 2 and prostaglandin E 2 . 9 Because NSAIDs also inhibit the formation of prostacyclin (PGI 2 ) 9 and inhaled PGI 2 has also proved effective in treating ARDS, 10 it is possible that NSAIDs may be intrinsically "self-defeating" in this particular scenario. Notably, we have recently demonstrated that PGI 2 inhibits the formation of O 2 ·Ϫ via a downregulation of NADPH oxidase activity induced by cytokines and endotoxin in pulmonary arterial cells. 11 NSAIDs would therefore remove this protective system, thereby augmenting oxidative stress and the depletion of NO as described above. In this context, inhaled NO has proved more effective in treating ARDS and reducing leukocyte activity and oxidant stress in ARDS. 12 NO acts at multiple sites to limit inflammation, including the inhibition of leukocyte and platelet adhesion and of release substances, including that of cytokines. 13 Because NO and PGI 2 have similar properties, including vasodilatation, the inhibition of adhesion molecule expression, inhibition of platelet and leukocyte activity, and a reduction in oxidative stress, 13, 14 it is reasonable to suggest that NO may also inhibit NADPH oxidase expression.
A novel class of NSAIDs that may be effective in treating ARDS is the NO-donating aspirins (NO-ASA). NO-ASA releases NO in vivo while retaining the antiinflammatory capacity of aspirin. 15 The donation of NO may also compensate for the inhibition of PGI 2 by NSAIDs. Indeed, drugs of this class have proved effective in preventing gastropathy associated with aspirin by virtue of their NO-donating capacity. 15 The NO moiety of NO-ASA may also act by preventing excess O 2 ·Ϫ formation, which, as proposed above, would be of potential therapeutic benefit in treating ARDS. To test these proposals, the effect of the NO-ASA adducts NCX 4016, NCX 4040, and NCX 4050 compared with an NO donor alone (morpholinosydnonimine, SIN-1) and ASA alone on O 2 ·Ϫ formation and gp91 phox (a catalytic subunit of NADPH oxidase) in response to cytokines and endotoxin in pig pulmonary artery vascular smooth muscle cells and endothelial cells was investigated.
Methods

Dissection of Pulmonary Arteries
Lungs were obtained from White Landrace male pigs of body weight ranging from 20 to 35 kg. All animal experiments were conducted in accordance with the rules and regulations of Bristol University and the Home Office for the care and use of experimental animals. Pigs were anesthetized with an intravenous injection of ketamine hydrochloride (10 mg/kg; Ketaset Injection, Fort Dodge Animal Health) and inhaled oxygenated halothane. The internal carotid artery was exposed, a cannula was placed in the carotid artery, and the animals were then exsanguinated. The chest was opened by median sternotomy, and the lungs were then excised from the chest. Pulmonary arteries (PAs) of 3-to 4-mm diameter were dissected from the lungs within 30 minutes and placed in DMEM with glutamax-1 (DMEM; GibcoBRL).
Culture of Pulmonary Artery Vascular Smooth Muscle Cells and Endothelial Cells
Pulmonary artery vascular smooth muscle cells (PAVSMCs) and endothelial cells (PAECs) were prepared according to previously published methods. 16, 17 PAECs were grown in endothelial cell growth medium (PromoCell) at 37°C in a 95% air-5% CO 2 incubator (Heraeus, Hera Cell, Kandro Laboratory Products). PAVSMCs were maintained in DMEM (supplemented with 10% FCS, 100 U/mL penicillin, and 100 g/mL streptomycin) at 37°C in a 95% air-5% CO 2 incubator. Subconfluent cultures of pulmonary VSMCs were growth arrested by washing in sterile PBS (GibcoBRL) and incubating in quiescing medium (serum-free DMEM supplemented with 0.5% lactalbumin hydrolysate, 100 U/mL penicillin, and 100 g/mL streptomycin) for 72 hours. Cultured cells were then incubated in fresh serum-free medium supplemented with the factor(s) under investigation.
Studies on the Source of O 2 ·؊ Formation Elicited by Endotoxin and Cytokines
PAVSMCs and PAECs were incubated with LPS (1 g/mL; Escherichia coli; 026:B6; Sigma Chemical Co), human recombinant IL-1␣ (10 ng/mL; R&D Systems) or human recombinant TNF-␣ (10 ng/mL); R&D Systems) at 37°C in a 95% air-5% CO 2 incubator. The measurement of O 2 ·Ϫ released by cells was performed by detection of ferricytochrome c reduction. 7 Thus, after incubation for 16 hours, pulmonary arterial cells were rinsed 3 times in PBS to remove drugs and stimulators and preequilibrated in DMEM without phenol red for 10 minutes at 37°C in a 95% air-5% CO 2 incubator. Then 20 mol/L horseradish cytochrome c (Sigma Chemical Co) with or without 500 U/mL copper-zinc superoxide dismutase (SOD; Sigma Chemical Co) was added to the segments or cells and incubated at 37°C in a 95% air-5% CO 2 incubator for 1 hour. The reaction medium was then removed, and the maximum rate of reduction of cytochrome c was determined at 550 nm by use of a temperature-controlled Anthos Lucy 1 spectrometer (Laboratory-tech International and converted to nanomoles of O 2 ·Ϫ by use of ⌬E 550 nm ϭ21.1 mmol · L Ϫ1 · cm Ϫ1 as the extinction coefficient for (reduced-oxidized) cytochrome c. The reduction of cytochrome c that was inhibitable with SOD reflected actual O 2 ·Ϫ release. Segments were blotted, dried, and weighed, data being expressed as nmol of O 2 ·Ϫ · mg tissue Ϫ1 · h Ϫ1 . Cells were rinsed in PBS and lysed with 0.1% vol/vol Triton-X100, and total protein content was measured by use of a BCA-protein assay kit (Pierce). Data are expressed as mol O 2 ·Ϫ · mg protein Ϫ1 · h Ϫ1 . To determine the source of the O 2 ·Ϫ , PAECs and PAVSMCs were preincubated with diphenyleneiodonium chloride (DPI; 10 mol/L) or apocynin (1 mol/L; NADPH oxidase inhibitors; Sigma Chemical Co), rotenone (10 mol/L; an inhibitor of mitochondrial respiration; Sigma Chemical Co), and allopurinol (100 mol/L; an inhibitor of xanthine oxidase; Sigma Chemical Co) for 2 hours before the measurement of O 2 ·Ϫ .
Effect of Nitroaspirins, SIN-1, and Aspirin on O 2
·؊
Formation and gp91 phox Expression
The NO-ASA adducts studied were NCX 4040 (2-acetoxybenzoate 2-(2-nitroxy)-butyl ester), NCX 4050 (2-acetoxybenzoate 2-(2-nitroxy-methyl)-phenyl ester, and NCX 4016 ((2-acetyloxy)benzoic acid 6-(nitrooxymethyl)-2-pyridinylmethyl ester chloride), which were supplied by NiCox SA. PAVSMCs or PAECs were incubated with LPS (1 g/mL), IL-1␣ (10 ng/mL), or TNF-␣ (10 ng/mL) in either the absence or the presence of (1) For Western analysis, the medium was removed after 16-hour incubation and the cells lysed with Tris buffer (50 mmol/L, pH 7.4) containing 1% vol/vol Triton X-100, EDTA (10 mmol/L) PMSF (1 mmol/L), pepstatin (0.05 mmol/L), and leupeptin (0.2 mmol/L). Extracts were boiled at a 1:1 ratio with Tris (50 mmol/L, pH 6.8, containing 4% wt/vol sodium dodecyl sulfate, 10% vol/vol glycerol, 4% vol/vol 2-mercaptoethanol, and 2 mg/mL bromophenol blue). Samples of equal protein (100 g) were loaded onto 12% Trisglycine SDS gels and separated by electrophoresis. After transfer to nitrocellulose, the blots were primed with a specific human antineutrophil gp91 phox antibody (2.5 g/mL final concentration) raised in mouse (a kind gift from Professor D. Roos, CLB, Amsterdam, the Netherlands). The blots were then incubated with goat anti-mouse immunoglobulin (Dako) conjugated to horseradish peroxidase (1:1000 dilution) and developed by enhanced chemiluminescence (Amersham International). Rainbow markers (14 to 220 kDa; Amersham) were used for molecular weight determination. 
Effects of Guanylyl Cyclase Inhibition
·؊
Although in preceding experiments, cells were washed free of drugs, their direct effects on O 2 ·Ϫ levels (quenching) was studied by use of a xanthine/xanthine oxidase system in the absence of cells. Nitroaspirins, aspirin, and SIN-1 (all 0 to 10 mol/L) were incubated with a xanthine (100 mol/L)/xanthine oxidase (0.15 U/mL) mixture (Sigma Chemical Co), which generates a steady flux of superoxide radicals, 11 and assayed for O 2 ·Ϫ formation by use of conditions identical to those described above.
Effect of Drugs on PGI 2 Formation
As mentioned in the introduction, the nitroaspirins possess the potential to compensate for the intrinsic negative effect of aspirin on PGI 2 formation. To confirm that nitroaspirins inhibit PGI 2 formation, PAVSMCs were seeded in 12-well plates, grown to confluence, and incubated for 16 hours with various concentrations of the nitroaspirin, aspirin, or SIN-1. After incubation, cells were washed with PBS, and PGI 2 formation was stimulated with calcium ionophore A23187 (10 mol/L; Sigma). 11 After incubation for 30 minutes at 37°C, supernatants were removed and aliquots taken for the measurement of PGI 2 (as 6-keto-PGF 1␣ ; R&D Systems) by use of enzyme-linked immunoassay kits. 11 
Statistical Analysis
Statistical analysis was performed by use of Instat (GraphPad Software Inc). Before the study was undertaken, power analysis was performed, from which it was determined that a number of nϭ6 was required for statistical assurance. Thus, data are expressed as meanϮSEM, nϭ6. Statistical analysis was performed by use of 1-way ANOVA or post hoc unpaired, 2-sided Student's t test with a Bonferroni adjustment. Statistical significance was assumed at a value of PϽ0.05.
Results
Source of O 2 ·؊ Formation Elicited by LPS, IL-1␣, and TNF-␣ by PAECs and PAVSMCs
LPS (1 g/mL) and TNF-␣ and IL-1␣ (both at 10 ng/mL) augmented O 2 ·Ϫ release from PAECs and PAVSMCs after a 16-hour time course (Figure 1 ). DPI and apocynin, both inhibitors of NADPH oxidase (but not rotenone or allopurinol) significantly inhibited O 2 ·Ϫ formation and release from PAECs and PAVSMCs after a 16-hour incubation with LPS, IL-1␣, and TNF-␣ (Figure 1) .
Effect of Nitroaspirins, NO Donor (SIN-1), Aspirin, and Guanylyl Cyclase Inhibitor (ODQ) on O 2 ·؊ Release and gp91 phox Expression
The nitroaspirins (NCX 4016, NCX 4040, or NCX 4050) and SIN-1 but not aspirin alone inhibited LPS-and cytokine-induced O 2 ·Ϫ release (Figures 2 and 3) . In both cell types, the maximum inhibition by nitroaspirins and SIN-1 was achieved at 0.1 mol/L, which was reversed by the addition of NO-sensitive guanylyl cyclase inhibitor, ODQ, in a dosedependent manner (Figure 4) , indicating that the cGMPprotein kinase G axis mediates this inhibitory effect of NO. Furthermore, nitroaspirins (NCX 4016 and NCX 4050) and SIN-1 also inhibited any increase in LPS-, IL-1␣-, and TNF-␣-induced gp91 phox protein expression in PAVSMCs ( Figure 5 ) and PAECs ( Figure 6 ). Aspirin alone, however, had no significant effect on LPS-or cytokine-induced gp91 phox expression in both cell types (Figures 5 and 6 ).
Effect of Nitroaspirins, SIN-1, and Aspirin on Quenching of O 2 ·؊ and PGI 2 Formation
The nitroaspirins, aspirin, and SIN-1 had no significant quenching effect on O 2 ·Ϫ generated by the xanthine/xanthine oxidase system (Table, top) . Nitroaspirins and aspirin all inhibited the formation of PGI 2 (as 6-keto-PGF 1␣ ) in a dose-dependent manner (Table, bottom ). In contrast, SIN-1 alone significantly elevated the PGI 2 levels produced by PAVSMCs (Table, bottom) .
Discussion
The present study demonstrates, first, that TNF-␣, IL-1␣, and LPS promote the formation of O 2 ·Ϫ in both PAVSMCs and PAECs in a time-dependent manner and at concentrations that have been reported to appear in the blood of patients with ARDS. 19 Furthermore, apocynin and DPI, both inhibitors of NADPH oxidase activity, completely inhibited the generation of O 2 ·Ϫ in response to TNF-␣, IL-1␣, and LPS, indicating that increased NADPH oxidase activity/levels mediate these effects, a conclusion confirmed by the upregulation of gp91 phox by TNF-␣, IL-1␣, and LPS. These data consolidate the proposition that the pathogenic effect of endotoxins and cytokines in ARDS may be mediated, in part, through an induction of intrapulmonary arterial oxidative stress. 1, 7 In a previous study, we demonstrated that the enhancement of O 2 ·Ϫ formation in intact pig pulmonary arteries by TNF-␣, IL-1␣, and LPS resulted in the formation of peroxynitrite (ONOO ·Ϫ ) 7 by the reaction between O 2 ·Ϫ and NO. 4 The lowering of NO bioavailability may result in vasoconstriction and pulmonary hypertension as well as a local increase in cytokines, because NO is a vasodilator 20 and prevents the adhesion of platelets and neutrophils. 20 ONOO ·Ϫ itself may be proinflammatory in this scenario, because it promotes adhesion molecule expression in leukocytes 21 and inhibits PGI 2 synthase activity. 22 In addition, in the present study, the NO donor SIN-1 inhibited gp91 phox expression and O 2 ·Ϫ formation through a guanylyl cyclase-dependent pathway, because the effects were reversed by ODQ. This effect could not be ascribed to a direct quenching effect, because the drugs were washed from of the system before O 2 ·Ϫ or gp91 phox expression was measured, and the nitroaspirins and SIN-1 had no effect on O 2 ·Ϫ generated by xanthine/xanthine oxidase in the absence of cells. Thus, endogenous NO formation may protect the pulmonary vasculature by preventing the expression of NADPH oxidase induced by LPS and cytokines. The con- verse is that the loss of NO availability by the overproduction of O 2 ·Ϫ would render the vasculature susceptible to augmented NADPH oxidase activity and therefore to increased NO destruction, thereby worsening the inflammatory cascades associated with ARDS.
In terms of treating ARDS, inhalational NO has been shown to be beneficial. 12 In the present study, not only SIN-1 but also the NO-donating aspirins inhibited O 2 ·Ϫ formation and NADPH oxidase upregulation, again via a cGMPdependent mechanism. In contrast, aspirin had no effect, indicating that the effects of the nitroaspirins are mediated by the NO rather than the aspirin moiety of the drug. Several studies have demonstrated that nitroaspirins exert both NOmediated effects and the inhibition of cyclooxygenase and therefore of the generation of proinflammatory eicosanoids, 15 such as thromboxane A 2 (TXA 2 ) and PGE 2 .
Although many clinical trials have demonstrated that NSAIDS are relatively ineffective in treating ARDS, 9 they have been shown to inhibit the formation of proinflammatory eicosanoids in patients with sepsis. 9 One possible explanation for the lack of efficacy of NSAIDs in ARDS is that they also inhibit the formation of the antiinflammatory eicosanoid PGI 2 . 14 The possible importance of endogenous PGI 2 in protecting against ARDS is exemplified by the therapeutic benefits of inhalational PGI 2 to treat the condition. 10 In a recent study, we also demonstrated that the PGI 2 analogue iloprost inhibits the expression of NADPH oxidase and O 2 ·Ϫ formation in pig PAVSMCs and PAECs, again induced by LPS and cytokines. 11 Thus, NSAIDs may intrinsically negate their therapeutic potential through this "double-edged" effect on PGI 2 . In the present study, the nitroaspirins inhibited PGI 2 formation but still blocked the gp91 phox expression and O 2 ·Ϫ formation. Thus, the NO-donating aspirins, by virtue of possessing an NO-donating moiety, may overcome this limitation of NSAIDs, because NO has properties similar to those of PGI 2 , including vasodilation and the inhibition of adhesion molecule expression and platelet and leukocyte activity. 13, 20 Notwithstanding NO and the lack of effect of ASA on NADPH oxidase activity, the aspirin moiety of NO-ASA may reduce vascular O 2 ·Ϫ formation through an indirect effect on platelet TXA 2 formation. We found that the TXA 2 analogue U46619 promoted O 2 ·Ϫ formation and NADPH oxidase expression in pig PAECs and PAVSMCs. 11 Because hyperactive platelets and increased TXA 2 formation is a hallmark of ARDS, 23 this inhibition may also be beneficial in attenuating oxidative stress and reducing the prohypertensive actions of TXA 2 . 14 One potential drawback of orally administered nitroaspirins, however, is their possible contraindication in sepsis, which etiologically accounts for 40% of ARDS patients. 23 In contrast to the pulmonary hypertension seen in ARDS, sepsis is associated with systemic hypotension, which is evoked by endotoxin-induced inducible NO synthase expression 24 and as such may be worsened by an NO donor. Indeed, it has been widely advocated that sepsis can be treated with inhibitors of NO synthase. 24 Nevertheless, in the remainder of patients with non-sepsis-mediated ARDS, nitroaspirins may still be appropriate.
In conclusion, this study demonstrates that LPS and cytokines promote the formation of O 2 ·Ϫ in pig pulmonary arterial cells via an upregulation of NADPH oxidase activity. This would lead to the negation of NO availability and the generation of ONOO ·Ϫ , which may render the vasculature susceptible to oxidative attack. The administration of nitroaspirins may be therapeutically useful in treating ARDS through (1) inhibition of leukocyte and platelet adhesion, (2) inhibition of release of cytokines from these blood cells, ( 
